Literature DB >> 19372474

Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.

Jeong Won Lee1, Jin Chul Paeng, Keon Wook Kang, Hyun Woo Kwon, Kyung-Suk Suh, June-Key Chung, Myung Chul Lee, Dong Soo Lee.   

Abstract

UNLABELLED: Although several prognostic factors are used to predict recurrence and to select adequate candidates for liver transplantation for hepatocellular carcinoma (HCC), these prognostic factors have some clinical limitations. The purpose of this study was to evaluate (18)F-FDG PET as a prognostic factor and to optimize its ability to predict tumor recurrence in liver transplantation for HCC.
METHODS: The study included a total of 59 HCC patients (45 men and 15 women; mean age +/- SD, 56 +/- 8 y) who underwent (18)F-FDG PET and subsequent orthotopic liver transplantation. All patients were followed up for more than 1 y (mean, 29 +/- 17 mo), and recurrence of tumor was monitored. Three PET parameters-maximal standardized uptake value (SUV(max)), ratio of tumor SUV(max) to normal-liver SUV(max) (T(SUVmax)/L(SUVmax)), and ratio of tumor SUV(max) to normal-liver mean SUV (T(SUVmax)/L(SUVmean))-were tested as prognostic factors and compared with conventional prognostic factors.
RESULTS: Among the 3 parameters tested, T(SUVmax)/L(SUVmax) was the most significant in the prediction of tumor recurrence, with a cutoff value of 1.15. In a multivariate analysis of various prognostic factors including T(SUVmax)/L(SUVmax), serum alpha-fetoprotein, T stage, size of tumor, and vascular invasion of tumor, T(SUVmax)/L(SUVmax) was the most significant, and only vascular invasion of tumor had additional significance. According to T(SUVmax)/L(SUVmax), the 1-y recurrence-free survival rate above the cutoff was markedly different from the rate below the cutoff (97% vs. 57%, P < 0.001).
CONCLUSION: In this study, (18)F-FDG PET was an independent and significant predictor of tumor recurrence. In liver transplantation for HCC, (18)F-FDG PET can provide effective information on the prognosis for tumor recurrence and the selection of adequate candidates for liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372474     DOI: 10.2967/jnumed.108.060574

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  53 in total

Review 1.  Liver transplantation for hepatocellular carcinoma.

Authors:  See Ching Chan
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

2.  Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma.

Authors:  Olivier Detry; Laurence Govaerts; Arnaud Deroover; Morgan Vandermeulen; Nicolas Meurisse; Serge Malenga; Noella Bletard; Charles Mbendi; Anne Lamproye; Pierre Honoré; Paul Meunier; Jean Delwaide; Roland Hustinx
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

3.  18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Misu Lee; Jeong Yong Jeon; Micheal L Neugent; Jung-Whan Kim; Mijin Yun
Journal:  Clin Exp Metastasis       Date:  2017-04-20       Impact factor: 5.150

4.  Extended Ischemia Times Promote Risk of HCC Recurrence in Liver Transplant Patients.

Authors:  Arno Kornberg; Ulrike Witt; Jennifer Kornberg; Helmut Friess; Katharina Thrum
Journal:  Dig Dis Sci       Date:  2015-01-29       Impact factor: 3.199

Review 5.  Liver transplantation for advanced hepatocellular carcinoma: how far can we go?

Authors:  Kyung-Suk Suh; Hae Won Lee
Journal:  Hepat Oncol       Date:  2015-01-12

6.  Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.

Authors:  Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

7.  18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Authors:  Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

Review 8.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

9.  Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.

Authors:  Maria-Angéla Castilla-Lièvre; Dominique Franco; Philippe Gervais; Bertrand Kuhnast; Hélène Agostini; Lysiane Marthey; Serge Désarnaud; Badia-Ourkia Helal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

Review 10.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.